[{"from": "human", "value": "Please give me some details about this molecule. [C][C][N][C][=C][C][=Branch2][Ring2][#Branch2][=N][C][=C][Ring1][=Branch1][C][=C][Branch1][Branch1][C][Ring1][#Branch2][=O][C][=C][C][=Branch1][#Branch2][=C][Branch1][=Branch1][C][=C][Ring1][=Branch1][Br][F][N][C][=Branch1][C][=O][N][C][=C][C][=C][C][=C][Ring1][=Branch1][N][C]"}, {"from": "gpt", "value": "The molecule is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and [imatinib]. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020.   It is the first drug approved as a fourth-line therapy in the specific setting of prior treatment with a minimum of 3 other kinase inhibitors."}]